# Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite

Source: https://onco.cc/trials/nct06176885/  
OnCo record `nct06176885` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of camrelizumab in colorectal cancer, run by yue junhan, now recruiting.

## Summary

Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer is a phase 2, interventional study registered as NCT06176885 by yue junhan, with a registry enrolment figure of 36 participants, started 2023-12-20 and due to reach its primary completion in 2025-12-20. Interventions recorded: Camrelizumab. Conditions listed: Colorectal Cancer. Primary outcome: PFS（Disease-free Survival）. Colorectal eligibility wording from the registry: "Metastatic colorectal cancer confirmed by histology and/or cytology and initially unresectable". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: FOBECAMS
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06176885
- Phase: 2
- Setting: Efficacy and Safety of Camrelizumab Combined With Irinotecan, Leucovorin and Fluorouracil (FOLFIRI) Chemotherapy and Bevacizumab Targeted Induction Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer: a Prospective, Multicenter, Single-arm Study
- Sponsor: yue junhan
- Enrolled: 36

## Sources

- ClinicalTrials.gov NCT06176885: https://clinicaltrials.gov/study/NCT06176885

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Camrelizumab](https://onco.cc/drugs/camrelizumab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06176885.json